论文部分内容阅读
目的探讨紫杉醇联合顺铂治疗晚期食管癌的方法和疗效,为临床治疗提供依据。方法回顾性分析2011年10月至2013年10月接受治疗的74例晚期食管癌患者的临床资料,以治疗方式的不同分为观察组和对照组,每组37例。对照组患者采用5-氟尿嘧啶联合顺铂治疗,观察组患者则采用紫杉醇联合顺铂治疗,对两组患者的近期疗效及毒副反应进行对比分析。结果治疗2个疗程(42 d)后,观察组总有效率为67.6%,对照组为29.7%,两组比较有统计学差异(P<0.01)。随访时间12个月,观察组33例患者,对照组31例患者获随访,观察组中位生存期及肿瘤进展时间[(10.5±2.2)、(6.7±1.4)个月]长于对照组[(9.1±1.5)、(4.7±1.2)个月,P均<0.05];两组患者主要不良毒副反应为脱发、骨髓抑制及胃肠道反应,且患者均可耐受。结论晚期食管癌患者给予紫杉醇联合顺铂治疗可取得较好的疗效,可有效延缓肿瘤进展时间,延长患者生存期,且毒副反应较轻,有较高的应用价值。
Objective To investigate the method and efficacy of paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer and provide the basis for clinical treatment. Methods The clinical data of 74 patients with advanced esophageal cancer who were treated from October 2011 to October 2013 were retrospectively analyzed. The observation group and control group were divided into observation group and control group with 37 cases in each group. Patients in the control group were treated with 5-Fluorouracil plus cisplatin, while patients in the observation group were treated with paclitaxel plus cisplatin. The short-term efficacy and adverse reactions were compared between the two groups. Results After two courses of treatment (42 days), the total effective rate in the observation group was 67.6% and that in the control group was 29.7%. There was significant difference between the two groups (P <0.01). The follow-up time was 12 months. 33 patients in the observation group and 31 patients in the control group were followed up. The median survival time and tumor progression time in the observation group [(10.5 ± 2.2), (6.7 ± 1.4) months] were longer than those in the control group [( 9.1 ± 1.5), (4.7 ± 1.2) months respectively, P <0.05]. The main adverse reactions in both groups were alopecia, myelosuppression and gastrointestinal reaction, and the patients were tolerant. Conclusion Paclitaxel combined with cisplatin in patients with advanced esophageal cancer can achieve better curative effect, which can effectively delay the time of tumor progression, prolong the survival time of patients, and have less toxic and side effects, which is of high value.